Neumora Therapeutics, Inc. (NMRA)
NASDAQ: NMRA · Real-Time Price · USD
0.6468
+0.0168 (2.67%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Neumora Therapeutics Stock Forecast
NMRA's stock price has decreased by -94.1% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Neumora Therapeutics stock have an average target of 9.29, with a low estimate of 1.00 and a high estimate of 20. The average target predicts an increase of 1,336.30% from the current stock price of 0.65.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Neumora Therapeutics stock from 8 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 3 | 3 | 2 |
| Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 6 | 6 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +673.04% | Apr 10, 2025 |
| B of A Securities | B of A Securities | Strong Buy → Sell Downgrades $7 → $1 | Strong Buy → Sell | Downgrades | $7 → $1 | +54.61% | Apr 2, 2025 |
| Guggenheim | Guggenheim | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Mar 10, 2025 |
| Stifel | Stifel | Strong Buy → Hold Downgrades $6 → $2 | Strong Buy → Hold | Downgrades | $6 → $2 | +209.21% | Mar 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +2,682.93% | Mar 7, 2025 |
Financial Forecast
Revenue This Year
n/a
from 290.13M
Revenue Next Year
n/a
EPS This Year
-1.51
from -1.53
EPS Next Year
-1.28
from -1.51
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 26.3M | 42.0M | ||
| Avg | n/a | 3.6M | 10.1M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 1,052.9% | ||
| Avg | - | - | 177.4% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.06 | -0.48 | -0.36 | ||
| Avg | -1.51 | -1.28 | -1.24 | ||
| Low | -1.71 | -1.72 | -1.81 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.